|
HHS Tobacco Control Steering Committee and Cessation Working Group
|
Committee, Work group, Advisory group, or Task Force
|
ACF, CDC, CMS, FDA, HRSA, OS, SAMHSA
|
NHLBI, NCI, NIDA
|
This committee, led by the Department of Health and Human Services, coordinates and initiates tobacco control activities across agencies. Helped to develop the HHS Tobacco Control Strategic Action Plan and the Action Plan Progress Report.
|
|
HHS Viral Hepatitis Interagency Working Group
|
Committee, Work group, Advisory group, or Task Force
|
AHRQ, CDC, CMS, FDA, HRSA, IHS, OS, SAMHSA
|
NIDDK, NIDA
|
The HHS Viral Hepatitis Interagency Working Group was created by the Office of the Assistant Secretary for Health to address a report sponsored by the Institute of Medicine entitled Hepatitis and Liver Cancer: A National Strategy for Prevention and Control of Hepatitis B and C. The group meets to discuss collaborations and activities directed at achieving the goals for viral hepatitis research and control highlighted in the IOM report. (Although NIDDK and NIDA represent NIH as Working Group members, other NIH Institutes/Centers/Offices also provide input to the VHIG through their participation in the Trans-NIH Committee on Viral Hepatitis.) The working group developed a 2017-2020 National Viral Hepatitis Action Plan.
|
|
HIV/AIDS Cancer Match Study
|
Research Initiative
|
CDC
|
NCI
|
Investigators use data from the NCI HIV/AIDS Cancer Match Study, in conjunction with data from the CDC HIV surveillance program, to estimate the burden of cancer in HIV-infected people in the United States.
|
|
HPV Working Group for the Advisory Committee on Immunization Practices (ACIP)
|
Committee, Work group, Advisory group, or Task Force
|
CDC
|
NCI
|
The HPV Working Group for the Advisory Committee on Immunization Practices (ACIP) Work Groups (WGs) serves in a key scientific role in support of vaccine policy development by the ACIP. ACIP WGs conduct extensive background reviews of relevant research data to develop options for recommendations for use of vaccines in the civilian population of the United States. WGs are convened solely to gather scientific information related to vaccines and the diseases they prevent, to analyze relevant issues and data, and to draft policies or options for review, deliberation, and vote by the ACIP.
|
|
HRSA childhood obesity technology challenge
|
Other
|
HRSA
|
NHLBI
|
NIH reviews grant applications submitted in response to HRSA''s childhood obesity technology challenge.
|
|
I-Corps @ NIH
|
Training Initiative
|
CDC
|
NCI, NCATS, NCCIH, NHGRI, NHLBI, NIA, NIAAA, NIAID, NICHD, NIDA, NIDCD, NIDCR, NIEHS, NIMH, NINDS
|
The I-Corps™ at NIH program is focused on educating researchers and technologists on how to translate technologies from the lab into the marketplace. The program is designed to provide three-member project teams with access to instruction and mentoring in order to accelerate the translation of technologies currently being developed with NIH and CDC SBIR and STTR funding. It is anticipated that outcomes for the I-Corps™ teams participating in this program will include significantly refined commercialization plans and well-informed pivots in their overall commercialization strategies.
|
|
Identifying Early Psychosis in Primary Care and Connecting to Care
|
Research Initiative
|
HRSA
|
NIMH
|
The Health Resources and Services Administration (HRSA) and National Institute of Mental Health (NIMH) are supporting testing of a brief early psychosis screening instrument. This instrument may be used in a primary care setting to identify people with psychosis at the earliest possible opportunity and connect them to an early psychosis treatment program.
|
|
Image-guided Interventional Therapeutics
|
Research Initiative
|
FDA
|
CC, NCI
|
This collaboration will lead to safer and more effective treatment planning and performance of image-guided interventions and therapeutic drug delivery. The results of all of these studies of image-guided interventions and related technologies and the models used to study them will have a direct impact on the effectiveness and consistency of the FDA Center for Devices and Radiological Health''s preclinical review of device applications while meeting the primary research goal of optimizing image-guided interventions and pre-clinical modeling of those interventions. Regulatory science and translational therapeutics have overlapping goals when it comes to drugs and devices combination therapies.
|
|
Immunology Interest Group
|
Meeting/ Workshop
|
FDA
|
NCI, CC, NCCIH, NCMHD, NEI, NHGRI, NHLBI, NIA, NIAAA, NIAID, NIAMS, NICHD, NIDA, NIDCD, NIDCR, NIDDK, NIEHS, NIGMS, NIMH, NIMHD, NINDS, OD/OIR
|
The NIH Immunology Interest Group brings together immunologists from across all NIH institutes as well as the FDA. The two major activities of the IG are a Wednesday afternoon lecture series highlighting world-class immunologists and intramural immunologists and an annual workshop where up to 350 NIH/FDA immunologists get together to present their work to the community.
|
|
Immunotoxicity of Workplace Xenobiotics
|
Research Initiative
|
CDC
|
NIEHS
|
The Immunotoxicity of Workplace Xenobiotics interagency agreement (IAG) functions to enhance the immunotoxicological evaluations of humans exposed to quantifiable levels of xenobiotics in the environment and workplace. To date work funded by this IAG has examined immune responses in diverse worker populations including farmers, healthcare and hospital workers, firefighters, and manufacturing workers (nanomaterials, lead batteries). A variety of occupational populations in the agriculture, forestry, service, and manufacturing sectors are at elevated risk of fungal exposures due to workers handling contaminated cellulose-based materials. The current projects focus on the growing concern of personal exposure to fungal bioaerosols and the potential toxicity of mold and mold-related xenobiotics from contaminated materials.
|